Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab With or Without Pazopanib in Soft Tissue Sarcomas
NCT03149120Phase 2Withdrawn
- Sponsor
- NYU Langone Health
- Start
- Aug 2017
- Primary completion
- Aug 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in soft tissue sarcoma (STS), bone sarcoma, sponsored by NYU Langone Health. Planned start Aug 2017; status: withdrawn.
02
Drugs
03
Conditions
soft tissue sarcoma (STS)bone sarcoma
Beyond the preview
Go deeper on NCT03149120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03149120.